ADHD Care at a Crossroads—A Comparative Policy Analysis

Across the United Kingdom, the United States and Canada, the understanding of ADHD as a healthcare issue that impacts people of all ages is finally gaining traction. As a result, demand for diagnostic and treatment services has exploded in all three countries.

ADHD has gained unprecedented attention in recent years, with skyrocketing demand for diagnostic and treatment services. In light of ongoing medication shortages, long waitlists, and shifting political landscapes, we decided it was time to conduct a fresh, concise 2025 analysis of ADHD policies in the UK, USA, and Canada. By comparing national-level initiatives, funding models, and advocacy efforts, we aim to highlight shared obstacles and identify best practices that can shape more effective ADHD care worldwide.

This condensed report offers key takeaways from a more extensive analysis. It explores:

• Core policies and funding for ADHD services in the UK, USA, and Canada
• Medication supply chain issues affecting individuals with ADHD
• Approaches to early intervention, diagnosis, and advocacy
• Practical recommendations for policymakers and stakeholders

I. ADHD Policy and Care in the United Kingdom

A. Recent National Policies and Initiatives:

The UK government has specific regulations concerning individuals with ADHD and their ability to drive ¹. The policy mandates that individuals must inform the Driver and Vehicle Licensing Agency (DVLA) if their ADHD or its medication affects their capacity to drive safely. Failure to do so can result in fines and potential prosecution in the event of an accident. However, if driving ability is not impacted, disclosure is not required. This policy extends to provisional license holders if a doctor advises that their ADHD or medication impairs safe driving ¹. For full car, motorcycle, bus, coach, or lorry license holders, notification to the DVLA is necessary only if there is a change in their condition that might compromise their driving safety ¹. This focus on individual responsibility for reporting the impact of ADHD on driving highlights a specific area where national policy intersects with the daily lives of those with the condition, emphasizing safety and legal obligations. The existence of this regulation suggests a governmental acknowledgment of ADHD's potential influence on activities beyond healthcare settings. The onus placed on individuals to self-report, guided by medical advice, indicates a system that relies on the awareness and proactive engagement of those affected.

NHS England initiated a significant project in December 2023 to thoroughly examine the provision of ADHD services within the National Health Service ². This rapid assessment identified several critical challenges hindering effective care. One major issue is the overwhelming demand for services, which current models struggle to accommodate. Furthermore, there is a lack of comprehensive and reliable data to fully grasp the extent of the need and the effectiveness of current provisions. The rapid expansion of the independent sector in delivering ADHD services also presents challenges, particularly concerning potential inconsistencies in service models and diagnostic thresholds. The programme also highlighted the need to find the right balance between the use of medication and therapeutic treatment options. Significant variations in access to services, patient experiences, and health outcomes across different populations were also noted. Finally, the assessment pointed to a lack of coordinated efforts across various sectors, including health, social care, education, and the justice system, in addressing the needs of individuals with ADHD ². Moving forward, NHS England recognizes the necessity of in-depth collaborative work with individuals who have ADHD, advocacy organizations, and other public bodies to gain a deeper understanding of these issues and to develop effective solutions ². This signifies a national-level recognition of the systemic issues within ADHD care in England, acknowledging the urgent need for intervention and policy adjustments. The commitment to collaborative efforts suggests a positive step towards a more inclusive and needs-based approach to improving services.

In England, the "Right to Choose" legislation grants patients the legal right to select their healthcare provider if their General Practitioner (GP) refers them to a consultant or specialist doctor ³. This policy extends to adult ADHD assessment and treatment, allowing individuals to opt for providers other than their local NHS services ³. Psychiatry UK has become a prominent provider under this scheme, offering online assessments and treatment for adult ADHD to NHS patients referred by their GPs ³. However, this service is currently experiencing unprecedented demand, leading to substantial waiting lists for both assessment and treatment ³. Notably, the "Right to Choose" is not available in Scotland, Wales, or Northern Ireland, creating a geographical disparity in access to this option ³. Furthermore, eligibility for the scheme is contingent upon being registered with a GP in England, and moving outside of England during the waiting period or treatment renders the patient ineligible ³. Recent developments indicate potential significant changes to the "Right to Choose" policy in England. NHS England has been consulting on proposals that could give local NHS areas (Integrated Care Boards or ICBs) the ability to restrict their patients' access to "Right to Choose" options ⁶. Concerns have been raised by advocacy groups like ADHD UK that these changes, if implemented, could lead to a drastic increase in waiting times for ADHD assessments, potentially from months to years ⁶. There are also fears that individuals currently receiving treatment under "Right to Choose" might have their care stopped ⁶. This policy represents a significant attempt to improve access to ADHD care by offering patient choice, but its limitations and the potential for its curtailment raise serious concerns about equitable care and the future of waiting times.

The Welsh government has demonstrated a clear commitment to improving services for neurodivergent individuals, including those with ADHD, through a significant investment of £13.7 million ⁷. This funding is specifically aimed at transforming existing services and reducing the often lengthy waiting times for autism and ADHD assessments across Wales. The investment will extend the work of the National Neurodivergence Improvement Programme until March 2027, building upon previous funding of £12 million over the past three years and an additional £3 million to address the longest waiting times for children's assessments ⁷. The Neurodivergence Improvement Programme has already achieved substantial progress in several key areas, including expanding workforce training across health, social care, education, and specialist sectors, piloting innovative needs-led profiling tools, enhancing data collection and reporting systems, establishing stronger collaborative relationships between organizations, piloting new integrated service delivery models, and holding an all-Wales accelerated design event ⁷. This financial commitment and the focus on these specific areas indicate a strategic and comprehensive approach to improving ADHD services at a regional level within the UK. The emphasis on a needs-led approach, exemplified by the West Glamorgan neurodiverse board's myth-busting project, which supports neurodivergent pupils based on their needs rather than solely on a diagnosis, signifies a positive shift towards early intervention and inclusive support ⁷.

The UK government offers the Access to Work programme, a valuable initiative designed to support individuals with ADHD and other disabilities in accessing or remaining in employment ⁸. This programme provides grants to fund necessary support that enables individuals to have a successful working life, and eligibility requires being in paid work for at least one hour a week, looking for work, or considering self-employment ⁸. Access to Work is a free service, and the support provided, such as equipment, ADHD coaching, and travel assistance, is funded through a grant ⁸. While employers are typically expected to contribute around 20% of the costs, the grant itself does not need to be repaid and does not affect other benefits received ⁹. The programme can cover a wide range of support tailored to individual needs, including ADHD coaching and training, assistive aids, standing desks, and mental health support ⁸. The annual funding per person can be significant, with a cap of £62,900 in 2021-2022 and £66,000 in 2023 ⁸. While a formal diagnosis of ADHD is not strictly required to qualify, having one significantly helps with the application process ⁹. The Access to Work programme represents a crucial policy that acknowledges the impact of ADHD on employment and provides tangible support for individuals in the workplace, aiming to foster inclusivity and reduce barriers to economic participation.

For individuals in England, Wales, and Northern Ireland who find themselves in a situation where there is no local NHS ADHD assessment service available, the option of an Individual Funding Request (IFR) exists ⁴. This process allows a clinician, typically the GP, to request funding from the local NHS to refer a patient for an assessment or treatment elsewhere. However, it's crucial to note that this option is specifically for cases where the service is entirely absent in the local area, not merely when there are long waiting lists ⁴. The clinician must recommend the assessment based on the National Institute for Health and Care Excellence (NICE) guidelines ⁴. In England, the "Right to Choose" pathway is often a more straightforward and commonly utilized alternative for accessing ADHD assessments compared to the IFR process ⁴. The existence of the IFR mechanism underscores the NHS's obligation to provide healthcare services outlined by national guidelines, even if local provision is lacking. It acts as a safeguard to ensure access when local resources are unavailable. However, the distinction between the absence of a service and long waiting times highlights a potential limitation, as individuals facing lengthy delays might still experience significant hardship in accessing timely care.

B. Funding Mechanisms and Commitments for ADHD Services:

As previously mentioned, the Welsh government has committed £13.7 million to enhance neurodivergence services, including ADHD, with the primary goal of reducing assessment waiting times ⁷. This targeted investment signifies a specific financial commitment at the regional level to address the growing demand for these services.

The Access to Work programme provides substantial funding in the form of grants, with an annual cap of £66,000 per individual, to support people with ADHD in the workplace ⁸. This funding is specifically allocated to cover costs associated with workplace adjustments, equipment, coaching, and other forms of support necessary for individuals with ADHD to succeed in their jobs.

In England, the funding for core NHS ADHD services is integrated within the broader NHS budget. While there isn't a specific ring-fenced amount solely for ADHD, initiatives like the NHS England ADHD Programme are aimed at understanding the challenges in service provision and ultimately improving resource allocation and service delivery for individuals with the condition ². This programme seeks to identify areas where resources can be used more effectively to meet the needs of the population with ADHD.

Funding for ADHD services in the UK operates through a multi-layered system involving national health budgets, targeted regional investments like the one in Wales, and specific programmes like Access to Work that focus on employment support. While this approach acknowledges the diverse needs of individuals with ADHD across different life domains, the persistent challenges identified by the NHS England ADHD Programme, such as overwhelming demand and unequal access, suggest that the current funding levels and allocation strategies may still fall short of what is required to provide timely and equitable care for all who need it. The competition for resources within the overall NHS budget also means that mental health services, including those for ADHD, may not always receive the priority or level of funding commensurate with their prevalence and impact.

C. Current State of ADHD Medication Supply Chains and Related Policy Changes:

Since Autumn 2023, the UK has been grappling with a significant national shortage of medications used to manage ADHD symptoms ³. This shortage has been attributed to a combination of manufacturing issues and a substantial increase in global demand for these medications. The supply problems have affected various medications and brands, including Methylphenidate (such as Concerta XL, Xaggitin XL, Xenidate XL, Equasym XL, Medikinet XL, Meflynate XL), and Lisdexamfetamine (Elvanse®) ¹³. In contrast, Guanfacine (Intuniv®) and Atomoxetine have generally remained more readily available ¹³. This shortage has had a profound impact on patients, causing delays in starting medication for newly diagnosed individuals and disruptions in treatment for those already established on medication ¹³. Patients have often been advised to contact multiple pharmacies in an attempt to locate their prescribed medication ¹³. In May 2024, the manufacturer Takeda, which produces several ADHD medications, reported that the majority of their products were back in stock, although they cautioned about potential short-term, intermittent disruptions for certain strengths as the supply situation continued to stabilize ¹⁵. However, despite these assurances, the medication supply chain in the UK remains fragile, with ongoing instability and intermittent stockouts of certain medications reported as late as July and September 2024 ¹⁴. Some healthcare services have even had to postpone new patient appointments for medication initiation due to the unreliable supply ¹². The prolonged and widespread nature of this medication shortage constitutes a major crisis in ADHD care within the UK, causing considerable anxiety, frustration, and disruption to the lives of individuals who rely on these medications to manage their symptoms and function effectively.

The provided information does not indicate any significant new national policies implemented by the UK government specifically to address the underlying causes of the ongoing ADHD medication shortage. The advice and guidance offered to patients and healthcare professionals, such as ordering prescriptions early, attempting to find medication at different pharmacies, and contacting prescribers for alternative advice, appear to be more in the nature of reactive management strategies to mitigate the immediate impact of the shortage ¹³. While the NHS England ADHD Programme has identified prescribing as a key area of interest and concern ², it is not clear from the available information whether this has yet translated into concrete policy changes aimed at strengthening the medication supply chain or preventing future shortages. The absence of proactive policy interventions to tackle the root causes of the supply issues suggests a potential gap in the national response to this significant challenge. While the government is undoubtedly aware of the problem, more systemic measures might be necessary to ensure a stable and reliable supply of essential ADHD medications for patients in the UK.

D. Policies and Discussions on Early Intervention, Diagnosis, and Support Services Across Age Groups:

The standard pathway for diagnosing ADHD in the UK typically begins with an individual, or the parents of a child, discussing their concerns with a General Practitioner (GP) ¹¹. The GP will inquire about the symptoms, their onset, the settings in which they occur, and their impact on daily life ¹¹. While GPs cannot formally diagnose ADHD, they can make a referral for a specialist assessment if necessary ¹⁷. For children suspected of having ADHD, GPs may initially suggest a period of "watchful waiting" for around 10 weeks and might also recommend group-based parent training or education programmes ¹¹. If the child's behaviour does not improve and is significantly affecting their daily life, the GP should then refer them to a specialist for a formal assessment ¹¹. For adults with possible ADHD, the GP will assess their symptoms and may refer them for an assessment if the symptoms began in childhood and have persisted, cannot be explained by another mental health condition, and significantly affect their day-to-day life ¹¹. Specialist assessments are usually conducted by child or adult psychiatrists, paediatricians, or other appropriately qualified healthcare professionals with expertise in ADHD diagnosis ¹¹. The assessment process involves a detailed evaluation, which may include a physical examination, interviews with the individual, and reports from significant others like partners, parents, and teachers ¹⁷. The diagnosis of ADHD in children depends on meeting specific criteria outlined in diagnostic manuals like DSM-5, typically requiring at least six symptoms of inattentiveness or hyperactivity/impulsivity for at least six months, with symptoms starting before the age of 12 and present in at least two different settings ¹¹. For adults, the criteria involve at least five symptoms that have been present since childhood and have a moderate effect on various aspects of their life ¹¹. It is important to note that in England, Wales, and Northern Ireland, the NHS follows the NICE guidelines on ADHD, which grant individuals a right to ADHD service provision ⁵. These guidelines were updated in 2019 regarding the need for an electrocardiogram (ECG) before starting medication ¹⁹.

Early intervention is a key focus in the UK's approach to managing childhood ADHD ²⁰. Recognizing the symptoms of ADHD early on is considered crucial for enabling children to develop the necessary skills to manage their symptoms and maintain a positive self-image ²⁰. Effective early intervention typically involves a combination of therapies, educational support, and active family involvement ²⁰. Behavioural therapies, such as Cognitive Behavioural Therapy (CBT) and Parent-Child Interaction Therapy (PCIT), are often employed by psychologists and psychiatrists to address inattention, hyperactivity, and impulsivity, as well as to develop social, emotional, and problem-solving skills ²⁰. Educational support is equally vital, with teachers and educators playing a significant role in creating individualized educational plans (IEPs) tailored to the child's unique learning needs, adjusting classroom routines, and utilizing assistive technologies ²⁰. Collaboration with the school's Special Educational Needs Co-ordinator (SENCO) is also essential ¹⁷. For children younger than 6 years old, parent training in behaviour management is typically recommended as the first-line intervention, aligning with international guidelines ¹⁷. Medication is generally considered for this age group only if behavioural interventions do not lead to significant improvement and under the guidance of a specialist mental health professional ²⁰. The UK government also has a broader policy emphasis on early intervention for children from conception to age five, addressing various aspects of their health, education, and social development ²⁴. This comprehensive approach underscores the importance of timely support for children with ADHD and their families.

A range of support services is available in the UK for individuals with ADHD and their families ²¹. The NHS provides resources such as advice for parents on managing children with ADHD, information on treatments like CBT and medication, and guidance on discussing ADHD with GPs, employers, and educational institutions ²¹. Several national charities and organizations offer crucial support, including AADD-UK, which specifically supports adults with ADHD and maintains a list of support groups ²¹. The ADHD Foundation provides a wide array of information, resources, and training for individuals, families, and professionals ²⁸. ADDISS (The National Attention Deficit Disorder Information and Support Service) offers people-friendly information and resources about ADHD to anyone in need ²⁸. The Brain Charity supports individuals affected by all neurological conditions, including ADHD, offering practical help, emotional support, and social activities ³¹. Additionally, the Access to Work programme provides employment-focused support ⁸, and numerous local support groups operate across the UK, offering peer support and community connections ²⁹. This robust network of services from both statutory and voluntary sectors aims to provide comprehensive support for the diverse needs of the ADHD community.

E. Perspectives and Statements from Prominent ADHD Advocacy Organizations:

The ADHD Foundation plays a significant role in the UK as a national charity providing a wide range of services related to ADHD ². Their work includes offering evidence-based information and resources tailored to individuals, families, educators, healthcare professionals, and businesses. They also provide training programmes, operate a screening clinic, and actively engage in advocacy to improve the lives of those affected by ADHD. Notably, the ADHD Foundation collaborates with the NHS England ADHD Programme, contributing their expertise and insights to the efforts aimed at understanding and addressing the challenges in ADHD service provision within the NHS ².

ADHD UK is another prominent national charity that is actively involved in advocacy and providing support for the ADHD community ⁴. They have been particularly vocal and active in opposing the proposed changes to the NHS Right to Choose policy in England, raising significant concerns about the potential for increased waiting times for assessments and reduced access to necessary treatment ⁶. ADHD UK also provides essential information and support to individuals seeking to access services like the Access to Work programme and has been a key voice in highlighting the ongoing national medication shortages, advocating for solutions and better support for affected patients ¹⁵.

ADDISS (The National Attention Deficit Disorder Information and Support Service) has served as a crucial resource in the UK for many years, providing user-friendly information and support regarding ADHD to a wide audience, including parents, individuals with ADHD, teachers, and healthcare professionals ²⁸. They offer a variety of resources, including a bookstore with extensive materials on ADHD and related conditions. ADDISS is also a member of ADHD Europe, an organization that advocates for the rights of individuals with ADHD at the European level ³⁰.

The Royal College of Psychiatrists, the professional body for psychiatrists in the UK, also plays a role in shaping ADHD care through the development of clinical practice guidelines and the publication of good practice guidance ²⁹. Their reports and position statements, such as the "ADHD in Adults - Good Practice Guidance," aim to provide a summary of current evidence-based practices to assist clinicians in the assessment, diagnosis, and treatment of ADHD ³³.

ADHD Action, a registered charity, has focused its efforts on lobbying for policy changes within central and local governments, as well as public sector bodies, since its inception ³⁴. A significant achievement of the organization was the establishment and ongoing work of the All Party Parliamentary Group for ADHD, which serves as a platform for raising awareness and advocating for better services at the parliamentary level ³⁴. However, it is important to note that ADHD Action is currently undertaking preparations to de-register in the coming months, with its financial assets intended to be donated to a larger ADHD charity ³⁴.

A significant statement reflecting the concerns of the ADHD community in the UK is the "Failure of Healthcare Provision. Consensus Statement" ³⁵. This document, endorsed by a group of UK experts representing clinical and healthcare providers from both public and private sectors, academia, ADHD patient groups, and educational and occupational specialists, highlights the concerning reality that despite the existence of evidence-based national guidelines, ADHD remains under-identified, under-diagnosed, and under-treated in the UK. The statement points to cultural and structural barriers within the healthcare system that contribute to the de-prioritization of ADHD. It also emphasizes that service provision is insufficient in many regions and has been further strained by the COVID-19 pandemic response. The consensus group calls for urgent action, including improved training for professionals, increased funding for services, better commissioning and monitoring of care, and more streamlined communication between health services to improve outcomes for individuals with ADHD. The statement also underscores the range of adverse outcomes and high long-term personal, social, health, and economic costs associated with untreated ADHD ³⁵.

II. ADHD Policy and Care in the United States

A. Current National Policies and Funding Initiatives under the Biden Administration:

The Biden-Harris administration has placed a significant emphasis on strengthening access to mental health care, a policy direction that has implications for individuals with ADHD seeking diagnosis and treatment ³⁶. A key initiative in this area is the final rule issued to reinforce the Mental Health Parity and Addiction Equity Act (MHPAEA) ³⁶. This rule mandates that health plans providing mental health and substance use care benefits must do so at the same level as they cover physical health care benefits. While not specifically targeted at ADHD, this policy aims to ensure that insurance coverage for mental health services, which would include the diagnosis and treatment of ADHD, is comparable to coverage for physical health conditions, thereby potentially improving affordability and access for millions of Americans with private health insurance ³⁶.

Recognizing the growing youth mental health crisis, the Biden administration has launched several initiatives aimed at bolstering mental health support for children and adolescents, which indirectly benefits those with ADHD ³⁸. These efforts include increased funding for school-based mental health services and grant opportunities to promote youth mental health and expand the behavioral health workforce ³⁹. Notably, President Biden has increased annual funding for Individuals with Disabilities Education Act (IDEA) grants by $1.4 billion since taking office ³⁸. IDEA guarantees the right of students with qualified disabilities, including ADHD (which falls under the "Other Health Impaired" category when symptoms impact educational performance), to participate in Individualized Education Programs (IEPs) that provide special education and related services and accommodations designed to improve their ability to receive academic instruction ⁴¹. Furthermore, the Department of Education plays a crucial role in enforcing Section 504 of the Rehabilitation Act of 1973 ³⁸. Section 504 ensures that students with disabilities, including ADHD, receive a "free appropriate public education" (FAPE) through the development of "504 plans," which can offer accommodations such as extra time on tests or special seating arrangements ⁴². However, it is important to note that Section 504 is currently the subject of a significant legal challenge (Texas v. Becerra) that could potentially impact its legal protections for millions of students with disabilities ⁴².

Under the Biden administration, the President's Make America Healthy Again Commission was established to aggressively combat critical health challenges facing American citizens, including rising rates of mental health disorders and other chronic diseases ⁴³. This commission is tasked with studying the scope of the childhood chronic disease crisis, which explicitly includes Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder ⁴³. The commission's mandate involves examining potential contributing causes, such as diet, environmental factors, medical treatments, and government policies, and providing recommendations to the President on policy and strategy related to addressing these issues and ending the childhood chronic disease crisis ⁴³. The commission is also directed to identify best practices for preventing childhood health issues through proper nutrition and healthy lifestyles and to evaluate the effectiveness of existing federal programs intended to prevent and treat these conditions ⁴³. The establishment of this commission signals a federal-level focus on understanding and addressing the increasing prevalence of childhood chronic diseases, with ADHD being recognized as a significant component of this crisis. The emphasis on prevention and holistic approaches suggests a potential future direction for policy that may involve lifestyle interventions alongside traditional medical treatments.

Beyond direct mental health initiatives, the Biden-Harris administration's efforts to address environmental health hazards also have implications for ADHD. The Environmental Protection Agency (EPA) estimates that the Lead and Copper Rule Improvements (LCRI) issued by the administration will, on average, prevent Attention-Deficit Hyperactivity Disorder (ADHD) in up to 2,600 children every year by requiring the replacement of lead pipes within ten years ⁴⁵. This highlights the recognition of environmental factors, such as lead exposure, as potential contributors to neurodevelopmental conditions like ADHD and demonstrates a policy aimed at reducing these risks.

President Biden signed a proclamation marking the 34th anniversary of the Americans with Disabilities Act (ADA), a landmark civil rights law that prohibits discrimination against people with disabilities in various aspects of life, including employment, public accommodations, and state and local government services ³⁸. This reaffirms the federal government's commitment to protecting the rights of individuals with disabilities, including those with ADHD, and ensuring their equal access and participation in society.

B. Analysis of Publicly Available Statements and Potential Policy Directions from Donald Trump and His Allies:

Statements and reports suggest that a potential Trump administration could take a significantly different approach to ADHD policy, particularly concerning the use of medication for children and adolescents ⁴⁴. A key indicator of this potential shift is the establishment of the Make America Healthy Again (MAHA) commission under a recent executive order ⁴⁴. While the current status of this commission might evolve, reports indicate that a similar body under a Trump administration would likely focus on scrutinizing and potentially restricting the prescription of psychotropic medications for youth, including stimulants commonly used to treat ADHD ⁴⁷. Concerns have been raised about the "over-utilization" of medication for conditions like ADHD ⁵⁰. The executive order reportedly mandates the MAHA commission to assess the prevalence and potential threat posed by the prescription of various medications, including stimulants, SSRIs, antipsychotics, and mood stabilizers, to children ⁴³. This focus on the potential risks of medication has drawn swift criticism and condemnation from medical experts and patient advocacy groups who emphasize that these medications, when prescribed and used appropriately under the care of trained psychiatrists, are safe, effective, and often life-saving ⁴⁶. Concerns have been voiced that such scrutiny could lead to unwarranted restrictions on access to necessary treatments for individuals with ADHD ⁴⁶.

Reviewing the mental health stances and actions of the Trump administration during his previous term provides further insight into potential future policy directions ⁴³. While in office, Trump signed the law establishing 988 as a nationwide mental health crisis line ⁵¹. However, his administration also voiced strong support for faith-based treatment programs and peer recovery initiatives, reflecting a belief in the importance of community and spiritual support in recovery ⁵¹. Trump also proposed a return to mental institutionalization for those with severe mental illness, a move away from the long-standing policy of community-based treatment ⁵³. His administration also expressed concerns about the over-reliance on medication for mental health conditions and emphasized the importance of nutrition, physical activity, and healthy lifestyles ⁴³. While there was a focus on the opioid crisis during his presidency ⁵², the overall approach to mental health, particularly concerning conditions like ADHD in children, suggests a potential skepticism towards medication and a preference for alternative or more restrictive approaches compared to the Biden administration's focus on parity and access. The emphasis on institutionalization for severe cases also contrasts with the current trend towards community-based care models.

C. Current State of ADHD Medication Supply Chains and Related Policy Changes:

Similar to the UK, the United States has been experiencing a significant and prolonged shortage of ADHD stimulant medications since 2022 ³. The shortage initially centered on immediate-release Adderall and its generic equivalents due to manufacturing delays at a major distributor ⁵⁷. However, the problem has since expanded to include various other stimulant medications used to treat ADHD, such as Ritalin, Concerta, and generic versions of Vyvanse ⁵⁷. Several factors have contributed to this shortage, including a substantial increase in demand for these medications, potentially driven by increased adult diagnoses and more relaxed prescribing rules during the COVID-19 pandemic, manufacturing issues, supply chain disruptions, and regulations imposed by the Drug Enforcement Administration (DEA) on the production quotas of controlled substances like ADHD stimulants ⁵⁵. This shortage has created significant challenges for patients, making it difficult to fill prescriptions, often requiring them to switch medications or, in some cases, go without medication entirely, leading to disruptions in their daily functioning, particularly in educational and work settings ⁵⁷. The DEA and the Food and Drug Administration (FDA) have acknowledged the shortage and have urged manufacturers with unused production quotas to relinquish them so that others can increase production ⁵⁷. The DEA also announced increases in the Annual Production Quota (APQ) for some manufacturers ⁵⁶. However, concerns remain about whether these measures will be sufficient to fully meet the current demand ⁵⁶. The rise in telehealth prescribing during the pandemic has also come under scrutiny as a potential contributing factor to the increased demand, with discussions and potential rule changes aimed at limiting the virtual prescribing of stimulants ⁵⁸. Furthermore, reports indicate that the prices of ADHD medications have also increased amid the short supply, adding financial pressure on patients and families ⁵⁹.

In response to the ongoing medication shortage, policy changes in the US appear to be focusing on two main areas: regulating the prescribing of stimulant medications, particularly through telehealth, and attempting to increase the overall supply through adjustments to production quotas. The DEA has proposed rules for permanent telemedicine flexibilities, which could impact how patients can access stimulant prescriptions ⁵⁹. Additionally, the DEA's adjustments to the Annual Production Quotas for manufacturers represent a direct regulatory response aimed at increasing the availability of these medications ⁵⁶. However, the effectiveness of these policy changes in fully resolving the shortage and ensuring a stable supply for all patients who need these medications remains to be seen. The complex interplay of increased demand, manufacturing challenges, and regulatory oversight suggests that a multi-faceted approach will be necessary to address this persistent issue.

D. Policies and Discussions on Early Intervention, Diagnosis, and Support Services Across Age Groups:

The diagnosis of ADHD in the United States relies on the criteria outlined in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) ⁶⁴. These criteria include specific thresholds for the number of symptoms of inattention and/or hyperactivity-impulsivity that must be present for at least six months, with onset before age 12 years and occurrence in two or more settings (e.g., home, school, work) ⁶⁴. The symptom thresholds differ slightly for children (up to age 16, requiring six or more symptoms) and for adolescents and adults (age 17 and older, requiring five or more symptoms) ⁶⁴. The diagnosis is typically made by qualified healthcare providers, including mental health professionals like psychologists and psychiatrists, as well as primary care providers such as pediatricians ⁶⁴. The American Academy of Pediatrics (AAP) has developed clinical practice guidelines for the diagnosis, evaluation, and treatment of ADHD in children and adolescents, which are widely endorsed and used by primary care providers ²⁵. These guidelines recommend a comprehensive evaluation process that includes gathering information from parents/guardians, teachers, and the child or adolescent themselves, using rating scales to document symptoms, ruling out other potential causes, and screening for co-occurring conditions ⁶⁵.

Early intervention is strongly emphasized in the US approach to ADHD, particularly for young children ²⁵. For children younger than 6 years of age, the AAP recommends parent training in behavior management as the first line of treatment, before medication is considered ²⁵. This recommendation is based on evidence showing that parent training can be as effective as medication for this age group and that young children tend to experience more side effects from ADHD medications ²⁵. For children 6 years of age and older, the AAP recommends a combination of FDA-approved medications along with behavior therapy, which includes parent training for children up to age 12 and other types of behavior therapy and training for adolescents ⁶⁵. Schools also play a crucial role in the treatment of ADHD, providing educational interventions, accommodations (such as through 504 plans), and behavioral supports within the classroom ⁶⁵. The rationale for early intervention is rooted in the understanding of brain plasticity in early childhood, the potential to prevent the onset of comorbid conditions, and the possibility of diminishing later impairment associated with ADHD ⁷⁰. Research continues to evaluate the efficacy and optimal delivery formats of behavioral parent education programs for young children at risk for or diagnosed with ADHD ⁷².

Several prominent national advocacy organizations in the US provide support and resources for individuals with ADHD and their families ⁷³. CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) is a leading organization that empowers people affected by ADHD by providing evidence-based information, supporting individuals and families, and advocating for equity and inclusion ⁷⁴. ADDA (Attention Deficit Disorder Association) focuses specifically on adults with ADHD, offering resources, support, and advocating for appropriate evaluation and treatment for adults living with the condition ⁷³. The World Federation of ADHD is an international organization that aims to disseminate knowledge about ADHD, promote research, and advocate for favorable public policy globally ⁷⁵. These organizations play a vital role in raising awareness, providing support networks, and advocating for the needs of the ADHD community in the United States.

E. Perspectives and Statements from Prominent ADHD Advocacy Organizations:

CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) stands as a major advocacy organization in the US, committed to providing evidence-based information, support, and advocacy for individuals and families affected by ADHD ⁷⁴. Their mission encompasses empowering people with ADHD throughout their lives, promoting understanding of the condition, and advocating for policies that ensure equity and inclusion. CHADD serves as a clearinghouse for information on ADHD, offers local support groups, and actively advocates for appropriate public policies in areas such as education, healthcare, and employment ⁷⁴.

The Attention Deficit Disorder Association (ADDA) focuses specifically on the needs of adults with ADHD ⁷³. Their mission is to empower adults with ADHD by providing support, resources, and fostering understanding of the unique challenges and strengths associated with adult ADHD. ADDA advocates for appropriate and comprehensive evaluations for adults and emphasizes that while medication can be an effective treatment, they do not specifically advocate for any particular medication. They also address issues such as over, under, and misdiagnosis of ADHD in adults, particularly women, and the importance of recognizing comorbid conditions ⁷³.

The World Federation of ADHD is an international organization with a mission to disseminate knowledge about ADHD, promote research into its causes and treatment, and formulate and promote public policy that favorably affects the care of individuals with ADHD ⁷⁵. They aim to facilitate the exchange of information among scientists, clinicians, advocacy groups, and the public, and to collaborate with other related professionals and organizations to improve outcomes for people with ADHD worldwide ⁷⁵.

The establishment of the Make America Healthy Again Commission under the Trump administration (as discussed in Section III.B) has drawn significant criticism and condemnation from medical experts and patient advocacy groups ⁵⁰. Concerns have been raised about the commission's focus on the "over-utilization of medication" for conditions like ADHD and autism, with fears that this could lead to harmful restrictions on access to necessary and effective treatments ⁵⁰. Organizations like the American Psychiatric Association (APA) have voiced strong opposition, emphasizing the safety and efficacy of psychiatric medications when prescribed appropriately ⁵⁰. Patient advocates have also expressed concerns that this initiative could be influenced by misinformation and could negatively impact individuals who rely on these medications to manage their ADHD and improve their quality of life ⁵⁰.

The ADHD Expert Consortium is a more recent initiative, formed by a group of healthcare professionals from diverse backgrounds who share a common vision of improving the standard of care for ADHD in the US, particularly for adults ⁷⁶. Their mission includes developing updated diagnosis and treatment guidelines for adults, expanding and improving screening processes for children, promoting the use of objective data in ADHD diagnosis, and enhancing education about ADHD for clinicians and the public ⁷⁶. The consortium aims to address the underdiagnosis of ADHD in adults and to reduce the stigma associated with the condition, advocating for a more standardized and evidence-based approach to ADHD care ⁷⁶.

III. ADHD Policy and Care in Canada

A. Recent National Policies, Funding Commitments, and Updates:

Unlike the UK and the USA, Canada does not have a single, overarching national ADHD policy established by the federal government ². While provinces have their own initiatives and healthcare systems, the federal government's role in directly shaping ADHD policy is less pronounced. However, advocacy organizations like the Centre for ADHD Awareness, Canada (CADDAC) and the Canadian ADHD Resource Alliance (CADDRA) have been actively advocating for the implementation of a national action plan to address the significant issues of under-recognition, under-diagnosis, and under-treatment of ADHD across the lifespan in Canada ⁸⁰. This proposed action plan focuses on three key pillars: empowering families and individuals with resources and knowledge to better recognize and understand ADHD and access care, educating medical and mental health practitioners in evidence-based approaches to assessment, diagnosis, and treatment, and ensuring that ADHD education is a curriculum requirement for all teacher training programs while equipping educators with the knowledge and resources to support students with ADHD and comorbid disorders ⁸⁰. The absence of a unified national policy framework distinguishes Canada's approach from that of the UK and the USA, where national-level guidelines and legislation play a more central role.

While a comprehensive national policy is lacking, various provincial-level initiatives and funding commitments exist across Canada. For example, in Alberta, researchers are focusing on early diagnosis and intervention, emphasizing the importance of providing children with ADHD with life skills and strategies for success into adulthood ⁹⁹. Manitoba announced a significant investment in 2007 to develop a multidisciplinary program for children with ADHD and their families, offering ongoing assessments and consultations ¹⁰⁰. In British Columbia, the ADHD Advocacy Society has been actively working to address the inadequate support services for children and youth with ADHD, highlighting the financial barriers and lack of understanding faced by families ⁹². These examples illustrate the decentralized nature of ADHD policy and funding in Canada, where individual provinces take the lead in developing and implementing their own approaches. This can lead to variations in the availability and quality of care depending on the province of residence.

The Canadian government does recognize ADHD as a disability, which is important for accessing various disability benefits at the federal and provincial levels ⁸³. This recognition allows individuals with ADHD who experience significant functional impairments to potentially qualify for financial and other forms of government support, such as the Disability Tax Credit, the Child Disability Benefit, and Canada Pension Plan Disability benefits ⁸³. This acknowledgement of ADHD as a condition that can lead to disability is a crucial step in providing a safety net for affected individuals and families.

In a notable development at the federal level, CADDRA received grant funding from Health Canada's Substance Use and Addictions Program in 2023 ⁸⁷. This grant is specifically supporting the development of an online course for medical, healthcare, and substance use professionals on the co-occurrence of ADHD and substance use disorders. This indicates a federal interest in supporting professional education and training related to ADHD, particularly in the context of comorbid conditions, even in the absence of a broader national ADHD policy.

B. Funding Mechanisms and Commitments for ADHD Services:

In Canada, the cost of ADHD assessment and diagnosis by medical professionals such as family physicians (with ADHD training), child and adolescent psychiatrists, and developmental pediatricians is generally covered by provincial healthcare plans ⁷⁷. However, assessments conducted by psychologists, who cannot prescribe medication, often require private funding or coverage through workplace benefits, which can pose a significant financial barrier for many individuals ⁷⁷.

Several disability benefits are available in Canada that individuals with ADHD may be eligible for. The Disability Tax Credit (DTC) is a non-refundable tax credit designed to help individuals with severe and prolonged impairments in physical or mental functions, including ADHD, reduce the amount of income tax they may have to pay ⁸³. The Child Disability Benefit (CDB) is a tax-free monthly payment provided to families who care for a child under age 18 with a severe and prolonged impairment who is also eligible for the DTC ⁸³. For adults with ADHD who are unable to work due to the severity of their symptoms, the Canada Pension Plan (CPP) Disability benefit offers long-term disability payments ⁸². Additionally, Employment Insurance (EI) sickness benefits can provide temporary disability support for individuals unable to work due to illness, including ADHD ⁸³. Some provinces also offer their own disability assistance programs ⁸⁴. Post-secondary students with permanent disabilities, including ADHD, may also be eligible for various grants and services through student aid programs ⁸⁶.

Funding for ADHD services in Canada is characterized by a mix of provincial government healthcare coverage for medical professionals, private funding for psychological services, and a range of federal and provincial disability benefits. This fragmented funding landscape can potentially lead to inequities in access to care depending on an individual's province of residence and their ability to afford or access private services. While the availability of various disability benefits provides crucial financial support for some, the eligibility criteria and application processes can be complex. The provision of student aid for those pursuing higher education is a positive aspect, helping to offset some of the additional costs associated with studying with ADHD.

C. Current State of ADHD Medication Supply Chains and Related Policy Changes:

While the provided snippets focus more extensively on the medication shortages in the UK and USA, there is evidence to suggest that Canada has also experienced similar challenges with the supply of ADHD medications ³. Snippet 3 mentions global drug shortages as a factor contributing to delays in prescribing ADHD medication in the UK, which would likely have implications for Canada as well, given the interconnectedness of international pharmaceutical supply chains. Reference ⁶¹ specifically discusses shortages of Adderall and other medications in both the US and Canada, indicating that Canadian patients have also faced difficulties in accessing their prescribed medications.

In response to potential shortages or difficulties in accessing specific stimulant medications, Canadian healthcare professionals may consider strategies such as substituting non-stimulant medications ⁶². While stimulants are often considered the most effective first-line treatment for ADHD, non-stimulant options like atomoxetine or guanfacine might be used as alternatives when stimulant medications are unavailable or not well-tolerated.

The Canadian ADHD Practice Guidelines, developed by CADDRA, have raised a specific concern regarding the use of generic versions of long-acting psychostimulant medications ⁸⁸. The CADDRA committee reported that some patients experienced a loss of symptom control when switched from original brand-name medications to generic equivalents. As a result of this observation, CADDRA generally recommends that long-acting psychostimulant generics be considered as second-line agents in the treatment of ADHD. This suggests a potential policy consideration for healthcare providers in Canada regarding the choice between brand-name and generic ADHD medications, particularly for long-acting formulations.

D. Policies and Discussions on Early Intervention, Diagnosis, and Support Services Across Age Groups:

The diagnostic process for ADHD in Canada involves a comprehensive evaluation of symptoms, often using the criteria outlined in the DSM-5, similar to the UK and USA ⁷⁷. This process typically includes a review of the individual's medical and psychiatric history, and for children, a review of childhood symptoms, potentially involving old report cards or discussions with parents ⁷⁷. Rating scales completed by the individual being assessed and a significant other are often used to gather information about symptoms and functional impairments ⁷⁷. In Canada, a diagnosis of ADHD can be made by various healthcare professionals, including family physicians (if they have received specific ADHD training), child and adolescent psychiatrists, developmental pediatricians, and psychologists (although psychologists in Canada cannot prescribe medication) ⁷⁷. Wait times for assessments can vary significantly depending on the type of professional and the region, and there can be associated costs, particularly for assessments conducted by psychologists, which may not be fully covered by provincial health plans ⁷⁷.

Early intervention for children with ADHD is also a key focus in Canada ²⁶. Current guidelines recommend a multimodal treatment approach that includes non-pharmacological interventions as part of the care plan ²⁶. For children younger than 6 years of age, parent behavior training (PBT) is considered the first-line intervention, consistent with recommendations in the UK and USA ²⁶. For school-aged children (6 years and older), a combination of behavioral management and medical management (pharmacotherapy) are typically the first-line interventions ²⁶. Psychoeducation for both the child and their family is also considered a crucial first step in the treatment process ⁸¹. Schools play an important role in supporting students with ADHD through accommodations and strategies to address learning and behavioral challenges ⁷⁷. Some provinces, like Manitoba, have implemented specific early intervention programs offering multidisciplinary support to children with ADHD and their families ¹⁰⁰.

Canada has national organizations dedicated to providing support and resources for individuals with ADHD. The Centre for ADHD Awareness, Canada (CADDAC) is a national charity that focuses on awareness, education, and advocacy for ADHD across Canada ⁷⁸. They provide resources for parents and individuals affected by ADHD, including support groups, coaching programs, and educational events ⁷⁸. The Canadian ADHD Resource Alliance (CADDRA) is primarily focused on healthcare professionals, developing and updating the Canadian ADHD Practice Guidelines and providing clinical support tools and training ²⁶. The Learning Disabilities Association of Ontario (LDAO) has also issued a policy statement recognizing the co-occurrence of ADHD and learning disabilities and advocating for the provision of services to individuals with ADHD as part of their overall program ⁹⁶.

E. Perspectives and Statements from Prominent ADHD Advocacy Organizations:

The Centre for ADHD Awareness, Canada (CADDAC) is a leading national charity in Canada dedicated to improving the lives of Canadians affected by ADHD through awareness initiatives, educational programs, and advocacy efforts ⁷⁸. CADDAC continuously develops programs and services for individuals with ADHD and their families, including support groups, coaching programs, and resource navigation assistance. They also actively advocate at all levels of the Canadian government for better ADHD treatment and awareness ⁷⁸.

The Canadian ADHD Resource Alliance (CADDRA) is a national organization primarily focused on healthcare professionals involved in the diagnosis and treatment of ADHD ²⁶. CADDRA's main activities include the development and regular updating of the Canadian ADHD Practice Guidelines, which are evidence-based and provide practical clinical advice for professionals. They also develop and disseminate key clinical support tools and resources, such as the ADHD Treatment Education and Assessment Tool (ADHD TrEAT) and ADHDLearn, aimed at enhancing the knowledge and skills of healthcare practitioners in managing ADHD ⁷⁸.

The Learning Disabilities Association of Ontario (LDAO) has recognized the significant overlap between ADHD and learning disabilities and has issued a policy statement advocating for the provision of services and support for individuals with ADHD as part of their broader mandate to support people with learning disabilities ⁹⁶. This highlights the understanding within the learning disabilities community in Canada of the interconnectedness of these neurodevelopmental conditions and the need for comprehensive support systems.

The ADHD Advocacy Society of BC is a provincial organization that champions equitable access to supports for people with ADHD in British Columbia ⁹². Established by ADHD self-advocates, the society conducts community engagement initiatives to understand the challenges faced by individuals with ADHD and their families in BC. Their recent survey revealed significant gaps in support, financial barriers, and a lack of understanding about ADHD within the province's support systems ⁹². The society actively advocates for changes to create a more equitable and supportive framework for those impacted by ADHD in British Columbia ⁹².

IV. Comparative Analysis of ADHD Care Approaches

A. Funding Models and Resource Allocation:

The UK operates primarily under the National Health Service (NHS), a centralized, publicly funded healthcare system. While core ADHD services are funded through the NHS budget, there are targeted investments like the £13.7 million in Wales for neurodivergence services ⁷. Additionally, the Access to Work programme provides significant grants for employment-related support ⁸. The Right to Choose policy in England offers patients more control over their care but faces potential restrictions ³.

The USA utilizes a mixed healthcare system with a combination of public and private insurance. Federal funding is allocated for special education through IDEA ³⁸ and for various mental health initiatives ³⁶. However, access to affordable healthcare remains a significant debate and challenge.

Canada has a publicly funded, decentralized healthcare system where provinces are primarily responsible for healthcare delivery. Assessment and diagnosis by medical professionals are generally covered provincially ⁷⁷, but psychological services often require private funding ⁷⁷. Various federal and provincial disability benefits are available ⁸³, and there are specific programs like student aid for individuals with disabilities ⁸⁶. The lack of a unified national ADHD policy can lead to regional disparities.

The UK's NHS provides a centralized funding structure, but it struggles with demand. The US system offers federal support but faces access issues. Canada's decentralized approach can lead to inconsistencies across provinces.

B. Key Policy Differences and Similarities Across the UK, USA, and Canada:

All three countries have national-level or widely adopted guidelines for ADHD diagnosis: the UK utilizes NICE guidelines ⁵, the USA relies on the DSM-5 and AAP guidelines ⁶⁴, and Canada uses CADDRA guidelines ²⁶, although the latter are not a national government mandate.

A unique policy in the UK is the Right to Choose in England, which allows patients to select their provider for adult ADHD care ³. The USA has Section 504 of the Rehabilitation Act, providing legal protection and accommodations for students with disabilities, including ADHD, in educational settings ³⁸.

All three nations have disability benefits that individuals with ADHD may be eligible for, but the specific criteria, application processes, and benefit amounts vary significantly between countries ⁸².

A notable similarity is the strong emphasis on early intervention for ADHD, particularly the prioritization of non-pharmacological approaches like parent training for young children (under 6) in all three countries ²⁵.

In summary, while a general consensus exists on the clinical approaches to ADHD, the structural differences in healthcare systems and the presence of specific legislation lead to distinct policy landscapes in each country.

C. Approaches to Medication Availability and Supply Chain Management:

A significant challenge shared by all three countries is the recent or ongoing shortage of ADHD medications ³. This highlights a global vulnerability in the pharmaceutical supply chain for these essential medications.

Contributing factors to these shortages include increased demand, manufacturing issues, and, particularly in the USA, regulatory constraints imposed by the DEA on production quotas ⁵⁵.

Policy responses have been largely reactive, with guidance provided to patients on how to manage the shortages ¹³. The USA has seen some regulatory responses, such as potential changes to telehealth prescribing rules and adjustments to production quotas ⁵⁶. However, there is a general lack of significant policy changes aimed at addressing the fundamental causes of these shortages in all three countries.

D. Strategies for Early Intervention, Diagnosis, and Support:

The diagnostic processes in the UK, USA, and Canada show similarities in their reliance on DSM or ICD criteria ⁵. However, the pathways to diagnosis and the roles of different healthcare professionals can vary. For instance, psychologists in Canada can diagnose but not prescribe medication ⁷⁷.

There is a strong consensus across all three countries on the importance of early intervention for ADHD. Parent training is consistently recommended as a key component for young children ²⁵. The crucial role of schools in providing educational and behavioral support is also widely recognized ⁴¹.

All three countries have well-established networks of advocacy organizations that play a vital role in providing information, resources, and support to individuals with ADHD and their families ²¹.

V. Conclusion

The comparative analysis of ADHD care across the UK, USA, and Canada reveals a shared commitment to recognizing and addressing this neurodevelopmental condition, yet significant differences exist in their policy frameworks, funding models, and approaches to service delivery. The increasing demand for ADHD services in all three regions underscores the growing awareness and the need for robust and responsive systems of care. The persistent and widespread shortages of ADHD medications represent a critical challenge that demands urgent attention and coordinated international efforts to ensure a stable supply for patients.

The UK's centralized NHS offers a structured system but faces capacity constraints and regional disparities, with the future of the Right to Choose policy in England adding further uncertainty. The USA demonstrates a strong emphasis on legal protections and educational support through IDEA and Section 504, alongside federal mental health initiatives, but affordability and access to care remain key concerns, particularly with potential shifts in administrative priorities. Canada's decentralized, provincially-led approach results in regional variations in service availability and funding, with advocacy organizations actively pushing for a more unified national strategy.

The strong consensus on the importance of early intervention, particularly the role of parent training and school-based supports, is a positive trend across all three countries. Additionally, the active and influential role of ADHD advocacy organizations in raising awareness, providing support, and lobbying for policy change is a common thread.

However, the findings of this analysis support the concern that North America and the UK must indeed do better in addressing the needs of individuals with ADHD. The challenges of long waiting times for diagnosis and treatment, the recurring crises in medication supply chains, and the persistent inequalities in access to care highlight areas where significant improvements are still needed. As ADHD care stands at a crossroads, it is imperative that policymakers in all three nations prioritize evidence-based practices, invest in adequate resources, and foster greater collaboration among healthcare professionals, educators, individuals with ADHD, and their families to ensure equitable and effective care for all.

Regional Recommendations

UK:

1. The UK government should urgently address the vulnerabilities in the ADHD medication supply chain through proactive measures such as diversifying suppliers, increasing domestic production capacity, and establishing clear communication protocols during shortages.
2. A thorough review of the proposed restrictions to the Right to Choose policy in England should be conducted, with careful consideration of the potential negative impact on waiting times and access to care. Alternative solutions to improve NHS capacity and reduce waiting lists across all regions of the UK should be explored.
3. Increased and sustained funding for NHS ADHD services is essential to meet the growing demand and reduce the current lengthy waiting times for assessment and treatment for both children and adults.

USA:

1. The US government should closely monitor and actively defend the legal protections provided by Section 504 of the Rehabilitation Act to ensure that students with ADHD continue to receive the necessary educational accommodations and support.
2. Any future policy considerations regarding medication for ADHD should prioritize evidence-based practices and ensure that access to safe and effective treatments is not unduly restricted, taking into account the perspectives of medical professionals and patient advocacy groups.
3. The ongoing ADHD medication shortage requires a multi-faceted approach involving the DEA, FDA, and pharmaceutical manufacturers to stabilize the supply chain, address production bottlenecks, and ensure consistent availability of all necessary medications.

Canada:

1. The Canadian federal government, in collaboration with provincial governments, should consider developing a more unified national ADHD policy framework to promote greater consistency and equity in diagnosis, treatment, and support services across all provinces and territories.
2. Increased public funding for ADHD services, particularly for assessments conducted by psychologists and for comprehensive treatment programs, would improve accessibility and reduce the financial burden on individuals and families.
3. The Canadian government should proactively monitor the ADHD medication supply chain and work with international partners and manufacturers to mitigate the risk of future shortages.

General Recommendations (All Regions):

1. Governments and research institutions should invest in further research to enhance the understanding of ADHD across the lifespan, including long-term treatment outcomes and the effectiveness of various interventions.
2. ADHD advocacy organizations in the UK, USA, and Canada should continue to be supported and empowered in their efforts to raise public awareness, reduce stigma, and promote evidence-based policies and practices.
3. Improved and standardized data collection on ADHD prevalence, diagnostic pathways, treatment modalities, and patient outcomes is crucial for informing policy development, service planning, and quality improvement initiatives in all three countries.
4. Efforts to foster greater collaboration and communication among healthcare professionals, educators, individuals with ADHD, and their families are essential for developing comprehensive and individualized care plans that meet the diverse needs of the ADHD community.

Works Cited

1. Attention deficit hyperactivity disorder (ADHD) and driving - GOV.UK, accessed on March 24, 2025, https://www.gov.uk/adhd-and-driving
2. Attention deficit hyperactivity disorder (ADHD) Programme update - NHS England, accessed on March 24, 2025, https://www.england.nhs.uk/long-read/attention-deficit-hyperactivity-disorder-adhd-programme-update/
3. Right to Choose ADHD Assessment and Treatment - Psychiatry-UK, accessed on March 24, 2025, https://psychiatry-uk.com/right-to-choose/
4. Individual Funding Request - ADHD UK, accessed on March 24, 2025, https://adhduk.co.uk/individual-funding-request/
5. Diagnosis pathways for Adult ADHD, accessed on March 24, 2025, https://adhduk.co.uk/diagnosis-pathways/
6. NHS Right to Choose Changes - ADHD UK, accessed on March 24, 2025, https://adhduk.co.uk/nhs-right-to-choose-changes/
7. £13.7 million to transform services and cut ADHD and autism waiting times | GOV.WALES, accessed on March 24, 2025, https://www.gov.wales/137-million-transform-services-and-cut-adhd-and-autism-waiting-times
8. Access to Work | ADHD Foundation, accessed on March 24, 2025, https://www.adhdfoundation.org.uk/wp-content/uploads/2022/07/ACCESS-TO-WORK.pdf
9. Access To Work - Support for Disabilities/ Health Conditions, accessed on March 24, 2025, https://adhduk.co.uk/access-to-work/
10. Access to Work ADHD Funding - Deepwrk, accessed on March 24, 2025, https://www.deepwrk.io/blog/access-to-work-adhd
11. How to Get an ADHD Diagnosis in the UK - Midland Health, accessed on March 24, 2025, https://midlandhealth.co.uk/2023/10/23/adhd-diagnosis/
12. National supply shortage of ADHD medication - Derbyshire Healthcare NHS Foundation Trust, accessed on March 24, 2025, https://www.derbyshirehealthcareft.nhs.uk/getting-help/understanding-your-medication/national-supply-shortage-adhd-medication
13. ADHD medication shortage: Important information for parents, accessed on March 24, 2025, https://bedslutonchildrenshealth.nhs.uk/news/2024/adhd-medication-shortage-important-information-for-parents/
14. Service updates - ProblemShared, accessed on March 24, 2025, https://www.problemshared.net/service-updates
15. ADHD drugs back in stock, says manufacturer - The Pharmaceutical Journal, accessed on March 24, 2025, https://pharmaceutical-journal.com/article/news/adhd-drugs-back-in-stock-says-manufacturer
16. Update on ADHD medication: July 2024 | Berkshire Healthcare NHS Foundation Trust, accessed on March 24, 2025, https://www.berkshirehealthcare.nhs.uk/news/news-archive/update-on-adhd-medication-july-2024/
17. Attention deficit hyperactivity disorder (ADHD) - Diagnosis - NHS, accessed on March 24, 2025, https://www.nhs.uk/conditions/attention-deficit-hyperactivity-disorder-adhd/diagnosis/
18. ADHD in adults - Royal College of Psychiatrists, accessed on March 24, 2025, https://www.rcpsych.ac.uk/mental-health/mental-illnesses-and-mental-health-problems/adhd-in-adults
19. Recommendations | Attention deficit hyperactivity disorder ... - NICE, accessed on March 24, 2025, https://www.nice.org.uk/guidance/ng87/chapter/recommendations
20. Early Intervention for Childhood ADHD: Treatment Options and Benefits, accessed on March 24, 2025, https://www.hsmh.co.uk/blog-posts/early-intervention-childhood-adhd
21. Living with Attention Deficit Hyperactivity Disorder (ADHD) - NHS, accessed on March 24, 2025, https://www.nhs.uk/conditions/attention-deficit-hyperactivity-disorder-adhd/living-with/
22. teaching and managing students with - ADHD Foundation, accessed on March 24, 2025, https://www.adhdfoundation.org.uk/wp-content/uploads/2022/03/Teaching-and-Managing-Students-with-ADHD.pdf
23. Attention training for infants at familial risk of ADHD (INTERSTAARS): study protocol for a randomised controlled trial - King's College London Research Portal, accessed on March 24, 2025, https://kclpure.kcl.ac.uk/portal/files/62874405/Attention_training_for_infants_.pdf
24. Early intervention: policy and provision - The House of Commons Library, accessed on March 24, 2025, https://commonslibrary.parliament.uk/research-briefings/cbp-7647/
25. Behavior Therapy First for Young Children with ADHD - CDC, accessed on March 24, 2025, https://www.cdc.gov/adhd/articles/behavior-therapy-first-young-children.html
26. ADHD in children and youth: Part 2—Treatment | Canadian Paediatric Society, accessed on March 24, 2025, https://cps.ca/documents/position/adhd-2-treatment
27. www.nhs.uk, accessed on March 24, 2025, https://www.nhs.uk/conditions/attention-deficit-hyperactivity-disorder-adhd/living-with/#:~:text=AADD%2DUK%20is%20a%20charity,for%20adults%2C%20parents%20and%20carers
28. Tips for everyday living | ADHD and mental health - Mind, accessed on March 24, 2025, https://www.mind.org.uk/information-support/tips-for-everyday-living/adhd-and-mental-health/
29. Support Groups | The UK ADHD Partnership, accessed on March 24, 2025, https://www.ukadhd.com/support-groups.htm
30. ADDISS, accessed on March 24, 2025, http://www.addiss.co.uk/
31. Attention deficit hyperactivity disorder (ADHD) - Support for neurological conditions | The Brain Charity, accessed on March 24, 2025, https://www.thebraincharity.org.uk/condition/attention-deficit-hyperactivity-disorder/
32. Home - ADHD Foundation : ADHD Foundation, accessed on March 24, 2025, https://www.adhdfoundation.org.uk/
33. Attention deficit hyperactivity disorder (ADHD) in adults: Good practice guidelines - Royal College of Psychiatrists, accessed on March 24, 2025, https://www.rcpsych.ac.uk/docs/default-source/improving-care/better-mh-policy/college-reports/cr235-adhd-in-adults---good-practice-guidance.pdf
34. ADHD ACTION - Charity Commission, accessed on March 24, 2025, https://register-of-charities.charitycommission.gov.uk/en/charity-search?p_p_id=uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet&p_p_lifecycle=2&p_p_state=maximized&p_p_mode=view&p_p_resource_id=%2Faccounts-resource&p_p_cacheability=cacheLevelPage&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_objectiveId=A11292453&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_priv_r_p_mvcRenderCommandName=%2Faccounts-and-annual-returns&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_priv_r_p_organisationNumber=5111563
35. Failure of Healthcare Provision for Attention-Deficit/Hyperactivity Disorder in the United Kingdom: A Consensus Statement | ADHD Foundation, accessed on March 24, 2025, https://www.adhdfoundation.org.uk/wp-content/uploads/2022/04/Failure-of-Healthcare-Provision.-Consensus-Statement.pdf
36. FACT SHEET: Biden-Harris Administration Lowers Mental Health Care Costs by Improving Access to Mental Health and Substance Use Care | The White House, accessed on March 24, 2025, https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2024/09/09/fact-sheet-biden-harris-administration-lowers-mental-health-care-costs-by-improving-access-to-mental-health-and-substance-use-care/
37. Health Care Week in Review: Biden Administration Announces $100 Million for ACA Marketplace Navigators and $81.3 Million for Mental Health, SUD Treatment, and Cancer Care | News & Insights | Alston & Bird, accessed on March 24, 2025, https://www.alston.com/en/insights/publications/2024/08/health-care-week-in-review-august-30-2024
38. FACT SHEET: The Biden-Harris Administration Marks the Anniversary of the Americans with Disabilities Act | The White House, accessed on March 24, 2025, https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2024/07/26/fact-sheet-the-biden-%E2%81%A0harris-administration-marks-the-anniversary-of-the-americans-with-disabilities-act-2/
39. Biden-Harris announces $46.8 million in behavioral health funding - Paubox, accessed on March 24, 2025, https://www.paubox.com/news/biden-harris-announces-46.8-million-in-behavioral-health-funding
40. CHILD AND ADOLESCENT MENTAL HEALTH - 2022 National Healthcare Quality and Disparities Report - NCBI Bookshelf, accessed on March 24, 2025, https://www.ncbi.nlm.nih.gov/books/NBK587174/
41. Department of Education and IEP Law: Are ADHD Students Services at Risk? - ADDitude, accessed on March 24, 2025, https://www.additudemag.com/department-of-education-iep-law-adhd/
42. Section 504 Under Threat - New America, accessed on March 24, 2025, https://www.newamerica.org/education-policy/edcentral/section-504-under-threat/
43. Establishing the President's Make America Healthy Again Commission - The White House, accessed on March 24, 2025, https://www.whitehouse.gov/presidential-actions/2025/02/establishing-the-presidents-make-america-healthy-again-commission/
44. Trump Establishes Commission Targeting Autism, Other Conditions - Disability Scoop, accessed on March 24, 2025, https://www.disabilityscoop.com/2025/02/18/trump-establishes-commission-targeting-autism-other-conditions/31304/
45. Biden-Harris Administration Issues Final Rule Requiring Replacement of Lead Pipes Within 10 Years, Announces Funding to Provide Clean Water to Schools and Homes | US EPA, accessed on March 24, 2025, https://www.epa.gov/newsreleases/biden-harris-administration-issues-final-rule-requiring-replacement-lead-pipes-within
46. ADHD Drugs Under Scrutiny by RFK Jr.'s Make America Healthy Again (MAHA) Commission, accessed on March 24, 2025, https://www.everydayhealth.com/mental-health-conditions/adhd-drugs-under-scrutiny-by-maha-commission/
47. 'Make America Healthy Again' Commission to Examine Use of Psychotropic Medications, accessed on March 24, 2025, https://psychiatryonline.org/doi/10.1176/appi.pn.2025.04.4.13
48. ASAN Condemns Announcement of President's “Make America Healthy Again” Commission and Harmful Ideas about Autism and Other Disabilities - Autistic Self Advocacy Network, accessed on March 24, 2025, https://autisticadvocacy.org/2025/02/asan-condemns-announcement-of-presidents-make-america-healthy-again-commission-and-harmful-ideas-about-autism-and-other-disabilities/
49. Trump administration putting mental health drugs for kids under new microscope - KIRO 7, accessed on March 24, 2025, https://www.kiro7.com/news/local/trump-administration-putting-mental-health-drugs-kids-under-new-microscope/A3NOEMDUYJDWXJZDRE2CFU2X3U/
50. Make America Healthy Again Commission Draws Criticism - ADDitude, accessed on March 24, 2025, https://www.additudemag.com/make-america-healthy-again-commission-criticism/
51. 2025 Federal Addiction & Mental Health Policy | BehaveHealth, accessed on March 24, 2025, https://behavehealth.com/blog/2025/2/10/2025-federal-addiction-and-mental-health-treatment-policies-under-the-trump-administration
52. APA Urges New Administration, Congress to Prioritize Mental Health | Psychiatric News, accessed on March 24, 2025, https://psychiatryonline.org/doi/10.1176/appi.pn.2025.03.3.41
53. Update: 3 Comparisons of Trump, Harris Mental Health Proposals; VOTE TODAY as if your life depends on it—Because it DOES! - The Alliance for Rights and Recovery, accessed on March 24, 2025, https://rightsandrecovery.org/e-news-bulletins/2024/11/05/update-3-comparisons-of-trump-harris-mental-health-proposals-vote-today-as-if-your-life-depends-on-it-because-it-does/
54. President Donald J. Trump Is Safeguarding Americans' Mental Health and Preventing The Tragedy of Suicide – The White House, accessed on March 24, 2025, https://trumpwhitehouse.archives.gov/briefings-statements/president-donald-j-trump-safeguarding-americans-mental-health-preventing-tragedy-suicide/
55. Adderall shortage may be associated with increased use of alternative ADHD medication in kids | Michigan Medicine, accessed on March 24, 2025, https://www.michiganmedicine.org/health-lab/adderall-shortage-may-be-associated-increased-use-alternative-adhd-medication-kids
56. US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment, accessed on March 24, 2025, https://www.ajmc.com/view/us-adhd-stimulant-shortage-highlights-growing-challenges-in-adult-treatment
57. Navigating the ADHD Medication Shortage in 2024 - Crescent City Psychiatric, accessed on March 24, 2025, https://crescentcitypsychiatric.com/navigating-medication-shortage/
58. ADHD Medication Shortage Continues as Diagnoses Surge - CU Anschutz newsroom, accessed on March 24, 2025, https://news.cuanschutz.edu/news-stories/adhd-medication-shortage-continues-as-diagnoses-surge
59. The Adderall Shortage: Why It's Still Happening and What to Do if You Can't Get Your Meds, accessed on March 24, 2025, https://www.everydayhealth.com/adhd/the-adderall-shortage-why-its-still-happening-and-what-to-do/
60. ADHD Medication: The Shortage Is Getting Worse | Psychology Today, accessed on March 24, 2025, https://www.psychologytoday.com/us/blog/its-not-just-in-your-head/202406/adhd-medication-the-shortage-is-getting-worse
61. What's behind shortages of Adderall, Ozempic and other meds? - CityNews Ottawa, accessed on March 24, 2025, https://ottawa.citynews.ca/2023/04/30/whats-behind-shortages-of-adderall-ozempic-and-other-meds/
62. Substituting ADHD Medications During the Stimulant Shortage | Psychology Today Canada, accessed on March 24, 2025, https://www.psychologytoday.com/ca/blog/1-2-3-adhd/202311/substituting-adhd-medications-during-the-stimulant-shortage
63. A 'perfect storm' led to an ADHD medication shortage. Here's why | PBS News, accessed on March 24, 2025, https://www.pbs.org/newshour/health/a-perfect-storm-led-to-an-adhd-medication-shortage-heres-why
64. Diagnosing ADHD | Attention-Deficit / Hyperactivity Disorder (ADHD) - CDC, accessed on March 24, 2025, https://www.cdc.gov/adhd/diagnosis/index.html
65. Clinical Care of ADHD | Attention-Deficit / Hyperactivity Disorder (ADHD) - CDC, accessed on March 24, 2025, https://www.cdc.gov/adhd/hcp/treatment-recommendations/index.html
66. ADHD in Children and Adolescents - AAFP, accessed on March 24, 2025, https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/ADHD.html
67. Attention-Deficit/Hyperactivity Disorder: AAP Updates Guideline for Diagnosis and Management | AAFP, accessed on March 24, 2025, https://www.aafp.org/pubs/afp/issues/2020/0701/p58.html
68. Attention-Deficit/Hyperactivity Disorder: What You Need to Know - National Institute of Mental Health (NIMH), accessed on March 24, 2025, https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-what-you-need-to-know
69. Treatment of ADHD | Attention-Deficit / Hyperactivity Disorder (ADHD) - CDC, accessed on March 24, 2025, https://www.cdc.gov/adhd/treatment/index.html
70. Preventive Interventions for ADHD: A Neurodevelopmental Perspective - PMC, accessed on March 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3441940/
71. How Early Intervention will Help your ADHD Child - Three Oaks Counseling & Psychiatry, accessed on March 24, 2025, https://threeoakstexas.com/how-early-intervention-will-help-your-adhd-child/
72. Early Intervention for Young Children At Risk for ADHD: Evaluating Efficacy and Delivery Format for Behavioral Parent Education, accessed on March 24, 2025, https://ies.ed.gov/use-work/awards/early-intervention-young-children-risk-adhd-evaluating-efficacy-and-delivery-format-behavioral
73. ADDA Position Statements - ADDA - Attention Deficit Disorder Association, accessed on March 24, 2025, https://add.org/policies/
74. About - CHADD, accessed on March 24, 2025, https://chadd.org/about/
75. Goals of the WFADHD - ADHD Federation, accessed on March 24, 2025, https://www.adhd-federation.org/about-us/Who-we-are.html
76. ADHD Expert Consortium Consensus Statement | Qbtech, accessed on March 24, 2025, https://www.qbtech.com/blog/adhd-expert-consortium/
77. General Info - CADDAC, accessed on March 24, 2025, https://caddac.ca/about-adhd/in-general/
78. CADDAC: Canadian ADHD Awareness | Education | Advocacy, accessed on March 24, 2025, https://caddac.ca/
79. Guide for Assessing Persons with Disabilities - How to determine and implement assessment accommodations - Attention Deficit Hyperactivity Disorder - Canada.ca, accessed on March 24, 2025, https://www.canada.ca/en/public-service-commission/services/public-service-hiring-guides/guide-assessing-persons-disabilities/guide-assessing-persons-disabilities/guide-assessing-persons-disabilities-determine-implement-assessment-accommodations-attention-deficit-hyperactivity-disorder.html
80. Creating Equitable Access to ADHD Care in Canada: Written Submission for the Pre-Budget Consultations in Advance of the Upcoming, accessed on March 24, 2025, https://www.ourcommons.ca/Content/Committee/441/FINA/Brief/BR11925078/br-external/Jointly04-e.pdf
81. Canadian ADHD Practice Guidelines (CAP-Guidelines) - The Canadian ADHD Resource Alliance, accessed on March 24, 2025, https://caddra.ca/pdfs/caddraGuidelines2011.pdf
82. www.resolutelegal.ca, accessed on March 24, 2025, https://www.resolutelegal.ca/adhd-disability-canada/#:~:text=CPP%20disability%20benefits%20for%20ADHD,%24583.32%20to%20%241%2C606.78%20per%20month.
83. ADHD Disability Canada: How to Apply for Government Benefits & More, accessed on March 24, 2025, https://www.resolutelegal.ca/adhd-disability-canada/
84. ADHD Disability Benefits Canada | Comprehensive 2025 Guide - Samfiru Tumarkin LLP, accessed on March 24, 2025, https://stlawyers.ca/law-essentials/adhd-disability-benefits-canada/
85. Child disability benefit (CDB) - Canada.ca, accessed on March 24, 2025, https://www.canada.ca/en/revenue-agency/services/child-family-benefits/child-disability-benefit.html
86. Financial Resources | Adult ADHD Centre, accessed on March 24, 2025, https://adultadhdcentre.com/living-with-adhd/financial-resources/
87. CADDRA Funding Sources, accessed on March 24, 2025, https://www.caddra.ca/overview/funding-sources/
88. Adult ADHD - Pharmacotherapy - CAMH, accessed on March 24, 2025, https://www.camh.ca/en/professionals/treating-conditions-and-disorders/adult-adhd/adult-adhd---treatment/adult-adhd---pharmacotherapy
89. Purchase Guidelines - ADHD Learn, accessed on March 24, 2025, https://adhdlearn.caddra.ca/purchase-guidelines/
90. Canadian ADHD Practice Guidelines (CAP-Guidelines) - Institut de pédiatrie sociale en communauté, accessed on March 24, 2025, https://institutpediatriesociale.com/wp-content/uploads/2020/03/Canadian-ADHD-Practice-Guidelines-Download-CADRRA.pdf
91. Canadian ADHD Practice Guidelines, 4.1 Edition, accessed on March 24, 2025, https://adhdlearn.caddra.ca/wp-content/uploads/2022/08/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf
92. ADHD Advocacy Society of BC, accessed on March 24, 2025, https://www2.gov.bc.ca/assets/gov/family-and-social-supports/children-teens-with-support-needs/adhd_advocacy_societys_report_2024_part_a.pdf
93. ADHD Advocacy Society of BC - Inclusion BC, accessed on March 24, 2025, https://inclusionbc.org/member/adhd-advocacy-society-of-bc/
94. adhd advocacy society of bc community engagement survey, accessed on March 24, 2025, https://www2.gov.bc.ca/assets/gov/family-and-social-supports/children-teens-with-support-needs/adhd_advocacy_society_of_bc_appendix_of_stakeholder_feedback_for_mcfd_2024_part_b.pdf
95. Centre for ADHD Awareness, Canada - ACT - Autism Community Training, accessed on March 24, 2025, https://www.actcommunity.ca/canada-resource/centre-for-adhd-awareness-canada/
96. LDA of Canada (LDAC) ADHD Resolution, adopted June 2007 - Learning Disabilities Association of Ontario, accessed on March 24, 2025, http://www.ldao.ca/wp-content/uploads/LDAO-Policy-Statement-on-ADHD.pdf
97. Non-pharmacological interventions - Canadian Paediatric Society, accessed on March 24, 2025, https://cps.ca/uploads/tools/ADHD-EN-clinician-guide.pdf
98. Approach to diagnosis and management of childhood attention deficit hyperactivity disorder - Canadian Family Physician, accessed on March 24, 2025, https://www.cfp.ca/content/cfp/66/10/732.full.pdf
99. Early diagnosis and intervention important for children with ADHD - University of Calgary, accessed on March 24, 2025, https://ucalgary.ca/news/early-diagnosis-and-intervention-important-children-adhd
100. PATHS - Early Intervention for ADHD | MCHP Concept Dictionary and Glossary for Population-Based Research | Max Rady College of Medicine | University of Manitoba, accessed on March 24, 2025, http://mchp-appserv.cpe.umanitoba.ca/supp.php/mchp/adhd.html

Dr. Adeel Sarwar, PhD, is a mental health professional specialising in a broad spectrum of psychological conditions such as depression, anxiety, ADHD, eating disorders, and obsessive-compulsive disorder (OCD). Armed with years of experience and extensive training in evidence-based therapeutic practices, Dr. Sarwar is deeply committed to delivering empathetic and highly effective treatment.